SLIT vs SCIT: Definitions, Evidence Base, and Safety Differential

SLIT stands for sublingual immunotherapy and SCIT stands for subcutaneous immunotherapy. Both are forms of allergen immunotherapy, the treatment class that gradually desensitizes the immune system to specific allergens rather than only relieving symptoms. SLIT delivers allergen under the tongue, where it is absorbed across the oral mucosa, and is taken daily at home. SCIT delivers allergen by injection into the subcutaneous tissue and is administered in a clinic under supervision. The two acronyms are widely used in allergy literature and clinical practice. In the United States, FDA-approved SLIT is available only as single-allergen tablets, while compounded multi-allergen liquid SLIT drops are used off-label.

The comparative evidence is mixed. The most cited network meta-analysis, Nelson et al. 2015 in the Journal of Allergy and Clinical Immunology: In Practice, found a near-zero symptom-score difference of 0.01 between SLIT and SCIT for grass pollen, supporting approximate equivalence. By contrast, Di Bona et al. 2012 conducted an indirect comparison that favored SCIT with larger effect sizes, though it carried substantial heterogeneity. Placebo-controlled Cochrane reviews show both routes meaningfully reduce symptoms. SCIT retains a stronger evidence base for cat, mold, and tree pollen. For grass and dust mite, the routes appear broadly comparable. Direct head-to-head randomized trials remain small and underpowered to resolve modest differences.

Safety is the clearest distinction between the two routes. SCIT carries a measurable systemic-reaction risk of roughly 0.1% per injection visit, and AAAAI surveillance attributes approximately one fatality per 2.5 million injections, which is why clinics enforce a 30-minute post-injection observation period. SLIT reactions are predominantly mild and local — and no fatalities have been reported worldwide; in our program fewer than 0.1% of patients have systemic reactions. The dominant SLIT side effects are local oral and gastrointestinal reactions such as mouth itching, which usually fade as tolerance builds. This differential underpins regulatory acceptance of at-home SLIT dosing after a supervised first dose, although epinephrine is still prescribed.

The SLIT evidence base draws on over 100 clinical studies, though the overall grade is reasonably consistent rather than definitive. The pivotal systematic review, Lin et al. 2013 in JAMA, analyzed 63 randomized controlled trials and found that SLIT reduces allergic rhinitis and rhinoconjunctivitis symptoms, with 9 of 36 relevant studies showing greater than 40% improvement. FDA-approved single-allergen SLIT tablets additionally carry strong phase-3 pivotal trial evidence for grass, dust mite, and ragweed. Compounded multi-allergen liquid drops, however, lack that standardized phase-3 evidence and are used off-label. The honest framing is that over 100 clinical studies support efficacy overall, with the strongest evidence for approved single-allergen tablets and thinner data for compounded multi-allergen drops.

Yes, both require a sustained multi-year course. The GRASS trial (Scadding et al., JAMA 2017) demonstrated that two years of either route was insufficient to produce benefit that persisted after stopping, establishing three years as the minimum for durable disease modification. Three to five years is the generally accepted course for both SLIT and SCIT. The schedules differ: SCIT involves weekly injections during build-up followed by maintenance dosing, while SLIT is taken daily at home throughout. Stopping early reduces the durability of benefit for either route. Patients should plan for a multi-year commitment and discuss the expected timeline and monitoring plan with their allergist before beginning treatment.